| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
NovaBridge Biosciences
13D/A
Amendment 2
NBP · 44975P103
|
11.5% |
2/3/2026
Event 1/29/2026
|
|||
| CBC Investment I-Mab Limited | 4.4% | ||||
| IBC Investment Seven Limited | 1.4% | ||||
| CBC Spvii Limited | 2.1% | ||||
| C-Bridge II Investment Ten Limited | 0.9% | ||||
| Nova Aqua Limited | 2.7% | ||||
| C-Bridge Healthcare Fund II, L.P. | 5.3% | ||||
| C-Bridge Healthcare Fund GP II, L.P. | 5.3% | ||||
| C-Bridge Capital GP, Ltd. | 8.8% | ||||
| I-Bridge Healthcare Fund, L.P. | 3.5% | ||||
| I-Bridge Healthcare GP, L.P. | 3.5% | ||||
| I-Bridge Capital GP, Ltd. | 3.5% | ||||
| Wei Fu | 11.5% | ||||
|
I-Mab
13D/A
Amendment 1
NBP · 44975P103
|
10.4% |
8/7/2025
Event 8/5/2025
|
|||
| CBC Investment I-Mab Limited | 4.5% | ||||
| IBC Investment Seven Limited | 1.4% | ||||
| CBC Spvii Limited | 2.1% | ||||
| C-Bridge II Investment Ten Limited | 0.9% | ||||
| Nova Aqua Limited | 1.6% | ||||
| C-Bridge Healthcare Fund II, L.P. | 5.4% | ||||
| C-Bridge Healthcare Fund GP II, L.P. | 5.4% | ||||
| C-Bridge Capital GP, Ltd. | 8.8% | ||||
| I-Bridge Healthcare Fund, L.P. | 3.5% | ||||
| I-Bridge Healthcare GP, L.P. | 3.5% | ||||
| I-Bridge Capital GP, Ltd. | 3.5% | ||||
| Wei Fu | 10.4% | ||||
|
I-Mab
13D
NBP · 44975P103
|
17.9% |
2/5/2025
Event 1/29/2025
|
|||
| CBC Investment I-Mab Limited | 6.3% | ||||
| IBC Investment Seven Limited | 1.9% | ||||
| CBC Spvii Limited | 3.0% | ||||
| C-Bridge II Investment Ten Limited | 1.3% | ||||
| Everest Medicines Limited | 3.2% | ||||
| Nova Aqua Limited | 2.2% | ||||
| C-Bridge Healthcare Fund II, L.P. | 7.6% | ||||
| C-Bridge Healthcare Fund GP II, L.P. | 7.6% | ||||
| C-Bridge Capital GP, Ltd. | 12.5% | ||||
| I-Bridge Healthcare Fund, L.P. | 4.9% | ||||
| I-Bridge Healthcare GP, L.P. | 4.9% | ||||
| I-Bridge Capital GP, Ltd. | 4.9% | ||||
| Wei Fu | 17.9% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.